Chávez-Capilla 2022 — Arsenolipid transformations in humans
This narrative review synthesizes current knowledge on arsenolipid species in seafood and fish oil, their bioaccessibility and bioavailability in the human gastrointestinal tract, and their potential transformation and accumulation in human tissues. The author frames arsenolipids as an underregulated food-safety concern because current regulatory limits for arsenic in food focus almost exclusively on inorganic arsenic (iAs), leaving the dominant arsenic species in seafood, which constitute 10–70% of total arsenic in oily fish, outside any formal limits. The review makes a case for interdisciplinary research into arsenolipid metabolism, particularly regarding gut microbiota and the blood-brain barrier, before regulatory agencies can act.
Key numbers
Total arsenic in seafood: 5–100 mg/kg (Francesconi, 2010; cited in text).
Arsenolipids in commercial fish oils: 0.2–16 mg/kg oil (Sele et al., 2012; cited in text).
Arsenic in rice: up to 0.4 mg/kg, of which 85–90% is iAs and the remainder is methylated species (methylarsonic acid, dimethylarsinic acid).
Arsenic in breast milk of Norwegian mothers eating fish-rich diets: 0.3–4.46 mg/kg; 2–61% of that fraction accounted for by arseno-fatty acids (AsFAs) and arseno-hydrocarbons (AsHCs) (Stiboller et al., 2017; cited in text).
Arsenic species distribution in seafood: arsenobetaine 1–70%, arsenosugars ~80% in seaweed, arsenolipids 10–70% in oily fish; iAs accounts for roughly 10% of total arsenic in most seafood species except Hijiki seaweed (nearly all iAs).
Regulatory limits cited: WHO drinking water limit 10 µg/L As; EU rice iAs limits 0.2 mg/kg for adults and 0.1 mg/kg for infants (European Commission 2015); Australia/New Zealand 1 mg/kg for seaweed and mollusks, 2 mg/kg for fish and crustaceans (total arsenic); France 3 mg/kg for seaweed for human consumption (iAs basis).
Intestinal absorption data from in vitro model: more than 50% of AsHCs and up to 13% of AsFAs remain unchanged after crossing the intestinal barrier (Meyer et al., 2015b; cited in text), indicating bioavailability.
Methods (brief)
Review article; no original laboratory data. Synthesizes published HPLC-ICP-MS, ESI-QQQ-MS, and HR-MS studies characterizing arsenolipid species. References in vitro intestinal barrier models, animal studies (Drosophila, rat brain tissue, mice), and limited human biomonitoring (breast milk, volunteer fish consumption trial). Key analytical limitation noted: no commercial certified standards for most arsenolipid species; detection requires advanced extraction and hyphenated mass spectrometry, available in only a few laboratories worldwide.
Implications
Certification: The review underscores that current arsenic food-safety frameworks (EU, WHO, Australia/New Zealand) target iAs almost exclusively. For seafood products and fish-oil-containing supplements, total arsenic figures are dominated by non-iAs species including arsenolipids, whose cytotoxicity is comparable to iAs in human cell lines. HMT&C product pages covering seafood, fish oil supplements, and omega-3-containing infant products should note that tAs measurements in these matrices cannot be treated as iAs proxies; speciation is essential.
Courses: Provides strong conceptual framing for a seafood arsenic speciation module: why tAs and iAs are non-substitutable; the regulatory gap for arsenolipids; gut microbiota as a modifier of arsenolipid bioavailability.
App: For seafood and fish-oil ingredients, the app should flag that total arsenic entries cannot be assumed to represent toxicologically relevant iAs exposure; these entries require a speciation note.
Microbiome: The review explicitly links gut microbial diversity to arsenolipid biotransformation and flags that salivary and intestinal microbiota transform methylated arsenic and arsenosugars before absorption. Maternal gut microbial diversity correlates with arsenic metabolite profiles in breast milk. This is a direct metals-microbiome mechanism warranting a dedicated microbiome cross-reference.